$GILD Recent News 14 stocks loved by top-performing

New Post Public Reply Private Reply Replies (0) Message Board

Sep 16, 2014 at 12:04 PM

$GILD Recent News

14 stocks loved by top-performing fund managers 10:05 a.m. Today - Philip van Doorn
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore
Surviving "a complex time in the market" 4:57 a.m. Aug. 25, 2014 - MarketWatch
10 S&P 500 companies growing faster than their rivals 3:29 a.m. Aug. 20, 2014 - Philip van Doorn
10 stocks enjoying the biggest increases in earnings estimates 7:27 p.m. Aug. 12, 2014 - Philip van Doorn
Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices 4:17 p.m. Aug. 8, 2014 - blogs.marketwatch.com
Gilead says EU Committee to recommend approval of leukemia drug 7:32 a.m. July 25, 2014 - Ciara Linnane
Gilead says EU Committee to recommend approval of leukemia drug 7:26 a.m. July 25, 2014 - Ciara Linnane
S&P 500 ekes out another record close: stock market live blog recap 4:03 p.m. July 24, 2014 - blogs.marketwatch.com
Facebook surges to record; SodaStream bubbles higher 1:23 p.m. July 24, 2014 - Tom Bemis
Biotechs beat estimates, but the Street wants more 11:44 a.m. July 24, 2014 - blogs.marketwatch.com
Gilead trounces earnings views, but shares don't feel the after-hours love 5:39 p.m. July 23, 2014 - blogs.marketwatch.com
Updates, advisories and surprises 5:31 p.m. July 23, 2014 - MarketWatch
Facebook rallies in after hours as results top outlook 4:58 p.m. July 23, 2014 - Sue Chang

Stock Market News for September 16, 2014 - Market News 10:10 a.m. Today - Zacks.com
ProQR Therapeutics: Competition, Distance From Clinical Trials Leads Us To Hold Off 9:53 a.m. Today - Seeking Alpha
If Achillion's Hep C Nucleotide Isn't Best In Class, The Stock Is Worth Low Single Digits 8:00 a.m. Today - Seeking Alpha
3 Hot Ways to Play the Biotechnology Bonanza 6:36 a.m. Today - InvestorPlace.com
'Fast Money' Recap: How Alibaba Is Hitting Momentum Stocks 5:00 a.m. Today - TheStreet.com
NPS Pharmaceuticals' Natpara Gets Positive FDA Panel Vote - Analyst Blog 7:05 p.m. Sept. 15, 2014 - Zacks.com
Alnylam Expands Pipeline with Preeclampsia Drug ALN-AGT - Analyst Blog 7:00 p.m. Sept. 15, 2014 - Zacks.com
Gilead to Allow Cheaper Hepatitis C Drug in Developing Countries 6:26 p.m. Sept. 15, 2014 - The Wall Street Journal Interactive Edition
Biogen/AbbVie Report Positive Data on MS Drug Zinbryta - Analyst Blog 5:50 p.m. Sept. 15, 2014 - Zacks.com
Novartis Presents Positive Data on Lucentis and Jetrea - Analyst Blog 5:35 p.m. Sept. 15, 2014 - Zacks.com
Abbott Labs Presents Positive One-Year Data on Absorb - Analyst Blog 5:20 p.m. Sept. 15, 2014 - Zacks.com
Amarin Plunges after the FDA Denies Vascepa SPA Appeal - Analyst Blog 4:45 p.m. Sept. 15, 2014 - Zacks.com
Eli Lilly's Cyramza Scores in Colorectal Cancer Study - Analyst Blog 4:30 p.m. Sept. 15, 2014 - Zacks.com
Genomic Health Reveals Positive Oncotype DX Test Results - Analyst Blog 3:00 p.m. Sept. 15, 2014 - Zacks.com
Is Intercept Pharmaceuticals Building The Next Great Specialty Franchise? 2:30 p.m. Sept. 15, 2014 - Seeking Alpha
3 Stocks Underperforming Today In The Drugs Industry 1:04 p.m. Sept. 15, 2014 - TheStreet.com
Jim Cramer Answers Twitter (TWTR) Questions on Alibaba IPO, Yahoo! (YHOO), Apple (AAPL) and More 12:47 p.m. Sept. 15, 2014 - TheStreet.com
U.S. Hepatitis Problem to Continue Driving These 4 Top Stocks 10:59 a.m. Sept. 15, 2014 - 247WallSt.com
Gilead OKs Generic Sovaldi To Expand Global Access 10:35 a.m. Sept. 15, 2014 - Investors Business Daily
Trade-Ideas: Gilead (GILD) Is Today's Pre-Market Laggard Stock 8:52 a.m. Sept. 15, 2014 - TheStreet.com

Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries 6:30 a.m. Sept. 15, 2014 - PR Newswire - PRF
Study Results, New Collaboration, Drug Designation, Technical Update, and Completion of Transaction - Research Reports on Gilead, AbbVie, Pfizer, United Therapeutics and Brookdale 9:10 a.m. Sept. 12, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Incyte Corp., Infinera Corporation, Ford and Pixelworks Released By InvestorsObserver 9:31 a.m. Sept. 9, 2014 - PR Newswire - PRF
Global Hepatitis C Market 2014-2018 9:58 p.m. Sept. 8, 2014 - PR Newswire - PRF
Upcoming Event, Drug Approval, Technical Updates, and Research Grant - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Thermo Fisher 9:20 a.m. Sept. 4, 2014 - PR Newswire - PRF
Gilead Sciences to Present at Two Upcoming Investor Conferences in September 5:00 p.m. Sept. 3, 2014 - BusinessWire - BZX
Technical Coverage on Biotech Equities - Galena Biopharma, Gilead Sciences, MannKind, Orexigen Therapeutics, and IsoRay 9:05 a.m. Sept. 3, 2014 - PR Newswire - PRF
Upcoming Conference Schedule, Scholarship, Approved Supplemental New Drug Application, and Technical Updates - Research Reports on Gilead, AbbVie, Pfizer, Express Scripts and Bard 9:10 a.m. Aug. 27, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Disney, Starbucks, Rockwell Medical and AT&T Released By InvestorsObserver 9:31 a.m. Aug. 21, 2014 - PR Newswire - PRF
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana 9:20 a.m. Aug. 19, 2014 - PR Newswire - PRF
Positive Opinion on the Drug, Acquisition, Orphan Drug Designation, Analysis Results, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Tenet Health 9:10 a.m. Aug. 8, 2014 - PR Newswire - PRF
Critical Alerts For Groupon, Gilead Sciences, Ballard Power Systems, GlaxoSmithKline, and Eli Lilly Released By InvestorsObserver 9:31 a.m. Aug. 4, 2014 - PR Newswire - PRF
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis 9:20 a.m. July 31, 2014 - PR Newswire - PRF
Market Momentum on Biotech Stocks -- IsoRay, Neurocrine Biosciences, OPKO Health, Orexigen Therapeutics, and Gilead Sciences 8:40 a.m. July 31, 2014 - PR Newswire - PRF
Theraclone Announces Exclusive Agreement with Gilead Sciences for Broadly Neutralizing HIV Antibodies 8:00 a.m. July 30, 2014 - BusinessWire - BZX
European CHMP Adopts Positive Opinion for Gilead’s Zydelig® (idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 7:24 a.m. July 25, 2014 - BusinessWire - BZX
Galectin, Intercept, Others Vying for Lead Drugs in NASH Epidemic 10:03 a.m. July 24, 2014 - ACCESSWIRE
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF) 12:30 a.m. July 24, 2014 - PR Newswire - PRF
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries 12:00 a.m. July 24, 2014 - BusinessWire - BZX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aurra Markets Wins 'Most Transparent Broker' Award 2026

Spotlight on Transparency in Trading Alright, so Aurra Markets snagged the 'Most Transparent Broker' award at the Money Expo in Mumbai this year. From the greasy streets of trading floors to the polished halls of Jio World Convention Centre, transparency is one of those golden words you hear tossed around, but like finding a needle in a haystack, it’s not always easy to...

LITEON Bets Big on Liquid Cooling with DCX Stake

Liquid Cooling: The AI Data Center Game Changer Alright, here's a twist in the tech saga that even a crusty old trader like me finds intriguing. LITEON (2301.TW) has made a bold move investing in DCX Liquid Cooling Systems with a $176 million deal for 25% equity. We're talking about liquid cooling here—it's the magic ingredient when your AI and HPC data centers start...

Ares Management Heads to Barclays Conference Spotlight

All Eyes on Ares – From the Trading Floor to Barclays Nothing like the crisp snap of traders' attention when big players like Ares Management Corporation (NYSE:ARES) are set to spill some beans at a fancy conference. Come September 16, 2026, Ares' head honcho, Michael Arougheti, will be hitting the stage at the Barclays Global Financial Services Conference. It’s the...

Curaleaf Eyes Growth: Conference Signals Opportunities

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Navimow's H5 Pro Mower Marries Tech with Nature Care

Garden Tech Reinvented: Enter the H5 Pro Mower Welcome to the 21st-century garden, where robotic ingenuity meets a genuine regard for nature. Folks, the Navimow H5 Pro just rolled onto the scene and it’s tearing up the old playbook of garden maintenance. It’s like blending Silicon Valley tech with Jane Goodall’s wildlife sensibilities. We're talking zero-edge...

Joseph Spine Opens New Regenerative Therapy Center

Regenerative Medicine: A New Frontier in Spine Care When spine care gets a facelift, you take notice. Joseph Spine Institute, a heavyweight in the spine care game, just threw hat into the regenerative ring. We're talking about using a patient's own cells to mend what's broken—that's advanced. They're launching a Regenerative Therapy Center in Tampa, ready to offer these...

Eosera Defies Odds with Texas-Made Ear Care Dominance

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Perspecta's Study Reveals Troubling Data Accuracy Gaps

Data Accuracy in Healthcare: A Persistent Problem Just when you think data's about numbers and cold, hard facts, healthcare jolts you awake. Perspecta's fresh insights onto provider data accuracy aren't just a snooze fest of statistics but a genuine wake-up call. This report peels open a can of worms some might prefer to ignore. With only half of provider data accurate,...

Nasdaq Flashes Warning Signs for Scage Future's Compliance

Two Strikes from Nasdaq: A Wake-Up Call? Scage Future's getting a double-shot of reality from Nasdaq after slipping under crucial thresholds. Here's the score: Scage's been dinged on their Market Value of Listed Securities (MVLS) and Market Value of Publicly Held Shares (MVPHS). Over a stretch from mid-July to late August, these benchmarks floundered below the line. The...

Alcatraz AI: A Silent Titan in Data Center Security

Why Alcatraz AI is the Security of Choice Forget flashy press releases and splashy marketing campaigns. Alcatraz AI, a company operating out of the hustle and bustle of Cupertino, has managed to quietly dominate a key sector without many folks being the wiser. What's their claim to fame, you ask? They're the chosen gatekeepers for over half of the hyperscale data centers...